Showing results (61-70 of 133) with videos related to
Sort By:
Pageof 14
Blood|July 2, 2002
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell doseCesare Guglielmi, William Arcese, Francesco Dazzi, et al.Journal of Hematology & Oncology|July 6, 2019
Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMTSimona Piemontese, Ariane Boumendil, Myriam Labopin, et al.American Journal of Hematology|July 24, 2018
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemiaFrancesco Saraceni, Eric Beohou, Myriam Labopin, et al.Bone Marrow Transplantation|February 2, 2022
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMTArnon Nagler, Myriam Labopin, Xiao-Jun Huang, et al.American Journal of Hematology|November 15, 2011
The potential role of pre-transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: a study from the Rome Transplant NetworkFrancesco Marchesi, Federica Giannotti, Giuseppe Avvisati, et al.Cancer Medicine|July 27, 2022
Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMTArnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, et al.American Journal of Hematology|June 15, 2017
Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationSandra Eder, Jonathan Canaani, Eric Beohou, et al.Haematologica|May 12, 2018
Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationDalila Salvatore, Myriam Labopin, Annalisa Ruggeri, et al.Haematologica|May 2, 2020
Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemiaArnon Nagler, Abraham S Kanate, Myriam Labopin, et al.Haematologica|March 17, 2022
Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trialFrancesco Buccisano, Raffaele Palmieri, Alfonso Piciocchi, et al.Pageof 14